Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials

By sjmartinez • February 11, 2023

Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, Paul C, Szepietowski JC, Tsai TF, Hampele I, You R, Charef P, Papavassilis C. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023 Feb 10;188(2):198-207. doi: 10.1093/bjd/ljac040. PMID: 36763857.

Tags: Dermatology, Publications

Corrigendum: Extracellular vesicles from human breast cancer-resistant cells promote acquired drug resistance and pro-inflammatory macrophage response

Santos P, Rezende CP, Piraine R, Oliveira B, Ferreira FB, Carvalho VS, Calado RT, Pellegrini M, Almeida F. Corrigendum: Extracellular vesicles from human breast cancer-resistant[...]

Stepwise neofunctionalization of the NF-κB family member Rel during vertebrate evolution

Daly AE, Chang AB, Purbey PK, Williams KJ, Li S, Redelings BD, Yeh G, Wu Y, Pope SD, Venkatesh B, Li S, Nguyen K, Rodrigues[...]

Emergency vs. Outpatient Care for Pediatric Atopic Dermatitis: A Population-Based Study of Sociodemographic Factors and Healthcare Utilization

Yamamoto RK, Tolson HC, Hao A, Kikuchi R, Sadrolashrafi K, Guo L, Bilimoria SN, Yee D, Armstrong AW. Emergency vs. Outpatient Care for Pediatric Atopic[...]